Karolinska Development appoints Bjerke CEO
This article was originally published in Scrip
Executive Summary
Karolinska Development (Sweden), an early-stage biotech investment company, has appointed Torbjörn Bjerke CEO. Mr Bjerke previously held the role of president and CEO of Orexo; before that he held the same roles at Biolipox, director of pharmacology at AstraZeneca and executive vice-president of R&D at ALK-Abello. He also continues to serve on the board of directors of NeuroSearch and DBV Technologies. Mr Bjerke succeeds Conny Bogentoft, who has led the company since 2003 but who will maintain an active role in the company.